Hydroxychloroquine Drugs Market Size, Growth, Trends, Report 2022 to 2030

According to Vision Research Reports, the global hydroxychloroquine drugs market size is expected to reach US$ 1.8 billion by 2030 from US$ 0.72 Bn in 2020, expanding at a CAGR of 10.3% from 2021 to 2030.

Hydroxychloroquine belongs to a class of drugs called antimalarials. It is used to treat rheumatoid arthritis and systemic lupus erythematosus by decreasing the activity of the immune system. In terms of disease indication, the global hydroxychloroquine drugs market has been classified into malaria, rheumatoid arthritis, COVID-19, systemic lupus erythematosus, and others. Based on distribution channel, the global hydroxychloroquine drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The rise in prevalence of malaria and rheumatoid arthritis and increase in geriatric population augment the global hydroxychloroquine drugs market.

Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/38175

High Prevalence of Malaria, Rheumatoid Arthritis, and Other Targeted Diseases to Drive Global Market

Hydroxychloroquine is FDA-approved to treat or prevent malaria. Hydroxychloroquine is also approved to treat autoimmune conditions such as chronic discoid lupus erythematosus, systemic lupus erythematosus in adults, and rheumatoid arthritis. According to the CDC, nearly half the world's population lives in areas at risk of malaria transmission in 91 countries and territories. In 2016, malaria caused an estimated 216 million clinical episodes and 445,000 deaths, which increased to an estimated 228 million cases and 405,000 deaths in 2018. Majority of deaths occurred in the WHO African Region. Systemic lupus erythematosus (SLE) is another most common autoimmune disease, in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. Hydroxychloroquine and corticosteroids (e.g., prednisone) are often used to treat SLE. The Lupus Foundation of America estimates that 1.5 million people in the U.S. and at least five million people across the world have a form of lupus. Ninety percent (90%) of people living with lupus are women.

Scope of The Report

Report Coverage

Details

Market Size By 2030

USD 1.8 Billion

CAGR from 2022 to 2030

10.3%

Largest Market

North America

Fastest Growing Region

Asia Pacific

Base Year

2021

Forecast Data

2022 to 2030

Key Players

Sanofi, Amneal Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Zydus Cadila, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, and Prasco Laboratories

 

High Prevalence of Childhood Arthritis Cases and Autoimmune Diseases Triggers Market Growth

The hydroxychloroquine drugs market is predicted to clock a robust CAGR of 10% during the forecast period. Hydroxychloroquine (Plaquenil) is considered as a disease-modifying anti-rheumatic drug. The high prevalence of joint pain and long-term disability in individuals has catalyzed the demand for hydroxychloroquine drugs. Plaquenil is being highly publicized for effectively reducing pain and swelling of arthritis.

An alarmingly high number of childhood arthritis cases and other autoimmune diseases are acting as key drivers for the hydroxychloroquine drugs market. However, the drug may lead to severe hypoglycemia. Thus, diabetic patients are advised to regularly monitor their blood sugar levels. On the other hand, it has been found that hydroxychloroquine is not effective against malaria in areas where chloroquine resistance has been reported. Hence, pharma companies are advocating a better understanding of poor quality drugs on malaria control.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38175

Pooled Analysis of Hydroxychloroquine Provides Drug Resistance Status

Hydroxychloroquine drugs are the gold standard for the treatment of malaria. However, in many cases, healthcare professionals have encountered drug resistance in patients, which is likely to affect the growth of the hydroxychloroquine drugs market. Poorly administered medicines and substandard treatments are affecting the sales of hydroxychloroquine drugs. Hence, manufacturers in the hydroxychloroquine drugs market are taking ques from the WorldWide Antimalarial Resistance Network (WWARN), which is facilitating study groups that generate a pooled analysis of the efficacy and safety of hydroxychloroquine drugs.

Freely available training courses, tools and resources are being employed to provide regional researchers with the knowledge and skills to generate high-quality antimalarial clinical data. As such, the FDA (Food and Drug Administration) approval for hydroxychloroquine is being highly preferred for rheumatoid arthritis and systemic lupus erythematosis treatment.

Decreased Disease Flares to Offset Disadvantages of Toxicity

The global hydroxychloroquine drugs market is expected to cross US$ 1.8 Bn by 2030, as manufacturers are increasing their output capacities that cater to the treatment of systemic lupus erythematosus. Research into the wide-ranging effects of hydroxychloroquine reveals that several benefits involving decrease in disease flares and decline in the number of antigen-presenting cells in the skin are bolstering market growth.

The decline in the damage from disease over time and the hydroxychloroquine’s ability to delay absorption of ultraviolet light (UV) are helping pharma companies boost their production capacities. However, patients with retinal dystrophy or macular degeneration are susceptible to toxicity due to hydroxychloroquine administration. Hence, companies in the hydroxychloroquine drugs market are encouraging patients to conduct annual examinations with qualified retina specialists to control toxicity levels.

Report Highlights

In terms of disease indication, the global hydroxychloroquine drugs market has been bifurcated into malaria, rheumatoid arthritis, COVID-19, systemic lupus erythematosus, and others. The rheumatoid arthritis segment dominated the market in terms of revenue in 2020. The increase in geriatric population also fuels the growth of the segment. The prevalence varies between 0.3% and 1% and is more common in women and in developed countries, as per WHO data.

Based on distribution channel, the global hydroxychloroquine drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global hydroxychloroquine drugs market in 2020. Large inventory maintained by hospitals and availability of essential drugs at hospital pharmacies are expected to drive the segment from 2020 to 2030. However, the online pharmacies segment is likely to expand at the highest CAGR during the forecast period. Increase in adoption of eCommerce and convenience offered by online pharmacies pharmacies are projected to drive the online pharmacies segment during the forecast period.

North America dominated the global hydroxychloroquine drugs market in 2020 and the trend is anticipated to continue during the forecast period. Well-established healthcare infrastructure and early adoption of advanced technologies are expected to boost the growth of the market in the region. Moreover, rise in prevalence of various types of targeted diseases increases demand for hydroxychloroquine drugs, which, in turn, fuels the growth of the market in North America. 

Asia Pacific is likely to be a highly lucrative market for hydroxychloroquine drugs during the forecast period. The market in the region is expected to grow rapidly over the next few years, due to increase in penetration and rise in awareness about biologic and biosimilar drug products in China. The country’s high market share can be attributed to the faster adoption of biologic and biosimilar drug products to treat chronic diseases such as rheumatoid arthritis and increase in geriatric population.

Key Players

Key players in the global market include Sanofi, Amneal Pharmaceuticals, Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Zydus Cadila, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Limited, and Prasco Laboratories. New product development through robust R&D activities and merger & acquisitions are the key strategies adopted by these players to operate business in the global hydroxychloroquine drugs market.

Market Segmentation

  • By Disease Indication
    • Malaria
    • Rheumatoid Arthritis
    • COVID-19
    • Systemic Lupus Erythematosus
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region
    • North America
    • Europe
    • Asia Pacific          
    • Latin America
    • Middle East & Africa

Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/38175

You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333

Back to news